Compass Pathways Plc ADR (CMPS) Stock Price, Quote & News

Company Profile

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company...

Industry: Medical Care Facilities

Sector: Healthcare

Phone: 44 716 6766461

Website: compasspathways.com

Address:

33 Broadwick Street, London, United Kingdom

T15K May. 13 at 11:46 AM

$CMPS are there any sales yet?

0 · Reply

ROCKYGEM711 May. 13 at 11:46 AM

$CMPS FYI Texting and speaking for the only person that I can and that's me I feel secure in adding to my position which is significantly large for my portfolio. Having the cash to carry CMPS through the year 2028 bodes well for my confidence in this company furthering this viable concern into the parabolic status. I now can understand the $70 Analysis call, The future can and will be bright. GL BULLS 😎

0 · Reply

texmade2 May. 13 at 11:38 AM

$CMPS I looking for $9.40 low for the day and I hope to load more there.

0 · Reply

texmade2 May. 13 at 11:33 AM

$CMPS I think PT for the moment is between $10.80 and $12.80

0 · Reply

WolfofTheCaribbean May. 13 at 11:19 AM

$CMPS hate to see Marty go but the market is reacting positively. Ill take it. Hope his successor is more actively involved in the priority vouchers

0 · Reply

texmade2 May. 13 at 11:14 AM

$CMPS let it go

0 · Reply

ROCKYGEM711 May. 13 at 11:01 AM

$CMPS It's a beat and can't wait to hear the earnings call COMPASS Pathways (CMPS) reported Q1 2026 results on May 13, 2026, beating analyst expectations with a loss of $\$0.30$ per share, better than the projected $\$0.43$ loss. Shares surged on the news, driven by strong cash reserves of $\$466$ million expected to fund operations into 2028 GL BULLS 😎 Bullish

0 · Reply

FBP May. 13 at 10:53 AM

$CMPS she broke 10!

0 · Reply

ClownThePoet May. 13 at 10:08 AM

$CMPS What time results out???

0 · Reply

texmade2 May. 13 at 4:06 AM

$CMPS 100%Extreme Bearish Breakout trade WATCH for possible breakout above 10 Target: 11.61

0 · Reply

Compass Pathways reports Q1 EPS (30c), consensus (31c)

2026-05-13T11:19:03.000Z - 31 minutes ago

Compass Pathways expects cash position to fund the company into 2028

May 13, 2026, 6:30 AM EDT - 1 hour ago

Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights

2026-05-07T18:24:07.000Z - 5 days ago

Psychedelic: Jefferies initiates Compass Pathways with a Buy rating

CMND ENVB JNJ NRXP SILO

May 6, 2026, 6:30 AM EDT - 7 days ago

Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026

May 6, 2026, 6:25 AM EDT - 7 days ago

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-05-03T23:55:09.000Z - 9 days ago

Compass Pathways initiated with a Buy at Jefferies

JNJ

2026-04-30T18:56:54.000Z - 12 days ago

Psychedelic: FDA awards Compass Pathways priority review voucher

CMND HELP SILO

Apr 27, 2026, 11:00 AM EDT - 15 days ago

COMPASS Pathways Transcript: Needham Virtual Psychedelics Forum

2026-04-24T17:41:05.000Z - 18 days ago

Oppenheimer says CNPV designation strengthens case for Compass Pathways’ COMP360

2026-04-24T14:45:52.000Z - 18 days ago

Compass Pathways announces FDA granted NDA rolling review request

Apr 24, 2026, 10:37 AM EDT - 18 days ago

Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher

2026-04-24T12:57:10.000Z - 18 days ago

Compass Pathways initiated with a Buy at B. Riley

2026-04-21T10:54:16.000Z - 22 days ago

Compass Pathways enters collaboration with Osmind

Apr 21, 2026, 6:30 AM EDT - 22 days ago

Compass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatments

Apr 20, 2026, 2:05 PM EDT - 22 days ago

How Trump's psychedelics executive order could unlock stalled cannabis reform

ATAI DFTX HELP GHRS

Apr 20, 2026, 10:45 AM EDT - 22 days ago

Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research

ATAI DFTX GHRS

Apr 20, 2026, 8:26 AM EDT - 22 days ago

Psychedelic stocks rally with Trump's support

ATAI DFTX GHRS

Apr 20, 2026, 8:18 AM EDT - 22 days ago

Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring.

ATAI GHRS DFTX

Apr 20, 2026, 6:43 AM EDT - 23 days ago

Psychedelic drug makers rally as Trump orders FDA to expedite reviews

ATAI DFTX ENVB GHRS HELP

Apr 20, 2026, 6:30 AM EDT - 23 days ago

Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 2026

2026-04-19T17:05:44.000Z - 23 days ago

Compass Pathways ‘commends’ White House Executive Order to accelerate research

Apr 18, 2026, 4:12 PM EDT - 24 days ago

Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments

Apr 14, 2026, 12:45 PM EDT - 4 weeks ago

COMPASS Pathways Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 14, 2026, 6:30 AM EDT - 4 weeks ago

Compass Pathways Announces U.S Grant Program for the Creation of Post-Approval COMP360 Provider Training

Apr 8, 2026, 6:30 AM EDT - 5 weeks ago

Compass Pathways to Attend Needham Virtual Healthcare Conference on April 14, 2026

2026-03-26T15:00:18.000Z - 6 weeks ago

Psychedelic: Compass Pathways, NRx Pharma report earnings results

ATAI GHRS NRXP

2026-03-25T21:35:15.000Z - 6 weeks ago

Compass Pathways price target lowered to $18 from $20 at Canaccord

2026-03-25T15:55:14.000Z - 6 weeks ago

Compass Pathways price target raised to $14 from $11 at Stifel

2026-03-25T12:15:17.000Z - 6 weeks ago

Compass Pathways price target lowered to $16 from $18 at Morgan Stanley

2026-03-24T11:35:57.000Z - 7 weeks ago

Compass Pathways reports Q4 EPS ($1.00) vs. (63c) last year

Mar 24, 2026, 7:30 AM EDT - 7 weeks ago

Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights

Mar 18, 2026, 10:30 AM EDT - 7 weeks ago

COMPASS Pathways Transcript: Stifel 2026 Virtual CNS Forum

Mar 12, 2026, 6:30 AM EDT - 2 months ago

Compass Pathways to Present at Stifel 2026 Virtual CNS Forum on March 18, 2026

Mar 3, 2026, 10:30 AM EST - 2 months ago

COMPASS Pathways Transcript: TD Cowen 46th Annual Health Care Conference

Feb 26, 2026, 6:30 AM EST - 2 months ago

Compass Pathways Announces Exercise of $200 Million in Outstanding Warrants

Feb 24, 2026, 6:39 AM EST - 2 months ago

Compass Pathways to attend TD Cowen 46th Annual Healthcare Conference in Boston, MA from March 2-4, 2026

Feb 18, 2026, 8:18 PM EST - 2 months ago

Compass Pathways Announces Pricing of $150 Million Public Offering

Feb 17, 2026, 4:06 PM EST - 3 months ago

Compass Pathways Launches Proposed $150.0 Million Public Offering

Feb 17, 2026, 8:00 AM EST - 3 months ago

COMPASS Pathways Transcript: Study update

Feb 17, 2026, 6:42 AM EST - 3 months ago

Compass Pathways' depression treatment meets main goal in late‑stage study

Feb 17, 2026, 6:30 AM EST - 3 months ago

Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

Feb 16, 2026, 8:00 AM EST - 3 months ago

Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials

Feb 9, 2026, 5:01 PM EST - 3 months ago

COMPASS Pathways Plc ADR (CMPS) Price Forecast: Bullish Reversal Gains Structure

Jan 7, 2026, 10:00 AM EST - 4 months ago

COMPASS Pathways Transcript: KOL Event

Jan 7, 2026, 6:30 AM EST - 4 months ago

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD

Jan 6, 2026, 6:30 AM EST - 4 months ago

Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360

Dec 9, 2025, 6:30 AM EST - 5 months ago

Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January 7, 2026, 10:00am ET

Dec 3, 2025, 1:30 PM EST - 5 months ago

COMPASS Pathways Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 10:00 AM EST - 5 months ago

COMPASS Pathways Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 20, 2025, 6:30 AM EST - 6 months ago

Compass Pathways to Participate in Two Investor Conferences in December

Nov 11, 2025, 10:40 AM EST - 6 months ago

COMPASS Pathways Transcript: Stifel 2025 Healthcare Conference

Nov 5, 2025, 6:30 AM EST - 6 months ago

Compass Pathways to Participate in Stifel 2025 Healthcare Conference

Nov 4, 2025, 8:00 AM EST - 6 months ago

COMPASS Pathways Earnings Call Transcript: Q3 2025

Nov 4, 2025, 6:45 AM EST - 6 months ago

Compass Pathways to expedite launch timing of its experimental depression therapy

Nov 4, 2025, 6:30 AM EST - 6 months ago

Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months

Oct 30, 2025, 8:30 AM EDT - 6 months ago

NeuroKaire Enters into R&D Collaboration with Compass Pathways to Pioneer Precision Treatments for Depression

Oct 29, 2025, 6:30 AM EDT - 7 months ago

Compass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors

Oct 28, 2025, 6:30 AM EDT - 7 months ago

Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025

Sep 2, 2025, 6:30 AM EDT - 9 months ago

Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder

Aug 27, 2025, 6:30 AM EDT - 9 months ago

Compass Pathways to Participate in Four Investor Conferences in September

Aug 12, 2025, 4:00 PM EDT - 9 months ago

COMPASS Pathways Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 5, 2025, 6:30 AM EDT - 10 months ago

Compass Pathways to Participate in Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 in Boston, MA

Jul 31, 2025, 8:00 AM EDT - 10 months ago

COMPASS Pathways Earnings Call Transcript: Q2 2025

Jul 31, 2025, 6:30 AM EDT - 10 months ago

Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights

Jul 29, 2025, 6:30 AM EDT - 10 months ago

Compass Pathways Appoints Justin Gover to Board of Directors

Jul 22, 2025, 6:30 AM EDT - 10 months ago

Compass Pathways to Announce Second Quarter Financial Results on July 31, 2025

Jul 10, 2025, 4:00 PM EDT - 10 months ago

Compass Pathways to Participate in HC Wainwright @Home Series Interview on July 14th, 8:00am ET

Jun 23, 2025, 8:12 AM EDT - 11 months ago

Compass Pathways stock slip as psilocybin depression trial falls short of expectations

Jun 23, 2025, 6:48 AM EDT - 11 months ago

Compass Pathways' depression drug succeeds late-stage trial

Jun 23, 2025, 6:30 AM EDT - 11 months ago

Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

May 20, 2025, 10:30 AM EDT - 1 year ago

COMPASS Pathways Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 14, 2025, 6:30 AM EDT - 1 year ago

Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference

May 8, 2025, 8:00 AM EDT - 1 year ago

COMPASS Pathways Earnings Call Transcript: Q1 2025

May 8, 2025, 6:30 AM EDT - 1 year ago

Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights

Apr 29, 2025, 6:30 AM EDT - 1 year ago

Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

Apr 28, 2025, 6:30 AM EDT - 1 year ago

Compass Pathways to Announce First Quarter Financial Results on May 8, 2025

Apr 22, 2025, 6:00 AM EDT - 1 year ago

Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Mar 28, 2025, 5:01 PM EDT - 1 year ago

This Is a Test From GlobeNewswire

ALVO

T15K May. 13 at 11:46 AM

$CMPS are there any sales yet?

0 · Reply

ROCKYGEM711 May. 13 at 11:46 AM

0 · Reply

texmade2 May. 13 at 11:38 AM

$CMPS I looking for $9.40 low for the day and I hope to load more there.

0 · Reply

texmade2 May. 13 at 11:33 AM

$CMPS I think PT for the moment is between $10.80 and $12.80

0 · Reply

WolfofTheCaribbean May. 13 at 11:19 AM

$CMPS hate to see Marty go but the market is reacting positively. Ill take it. Hope his successor is more actively involved in the priority vouchers

0 · Reply

texmade2 May. 13 at 11:14 AM

$CMPS let it go

0 · Reply

ROCKYGEM711 May. 13 at 11:01 AM

0 · Reply

FBP May. 13 at 10:53 AM

$CMPS she broke 10!

0 · Reply

ClownThePoet May. 13 at 10:08 AM

$CMPS What time results out???

0 · Reply

texmade2 May. 13 at 4:06 AM

$CMPS 100%Extreme Bearish Breakout trade WATCH for possible breakout above 10 Target: 11.61

0 · Reply

stocktwitsaccount69 May. 13 at 4:02 AM

$CMPS big jump?

0 · Reply

Millionaire11 May. 13 at 1:03 AM

$CMPS spravato generates 2 billion a year. $CMPS is projected to do at least the same if not more yearly. That puts $CMPS at a 6-10 billion dollar market cap. 3x-5x at least. Trust god

2 · Reply

Waldo_5150 May. 12 at 11:36 PM

$CMPS .... If we can stay above $9.00 tomorrow .... -- Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026 ..

0 · Reply

Waldo_5150 May. 12 at 10:48 PM

$CMPS ....... "Conclusions and Relevance In this randomized clinical trial, Psilocybin appeared to be safe and efficacious for treating cocaine use disorder among individuals from underrepresented and vulnerable populations" ...

0 · Reply

texmade2 May. 12 at 9:53 PM

$CMPS FDA Commissioner Dr. Marty Makary’s resignation on May 12, 2026, after a tumultuous tenure, is viewed as a positive development for biotech stocks, offering hope for increased regulatory stability and reduced controversy. Investors expect less volatility and more consistent drug approval processes, potentially boosting sector confidence following a period of high-profile, contested rejections

0 · Reply

BankOnTheFuture May. 12 at 7:36 PM

$CMPS $ATAI $DFTX $HELP Wonder if Makary being removed as FDA commissioner will have any effect on the psychedelic sector?

1 · Reply

ScorpionScarlet May. 12 at 6:54 PM

$CMPS so, what are we expecting from earnings? Up or down? 💕💸🥳

1 · Reply

Millionaire11 May. 12 at 6:25 PM

$CMPS I’ve never been in a stock that looks so good and is as stable as this one. The longer the coil up the farther it springs.

1 · Reply

Millionaire11 May. 12 at 6:16 PM

$CMPS bull flag on daily with bottom of flag forming at this $9.40

0 · Reply

Millionaire11 May. 12 at 4:01 PM

$CMPS this is an insane gift. This is the last time I’ll say it.

1 · Reply

texmade2 May. 12 at 3:31 PM

$CMPS wants to fill gap at 9.18

0 · Reply

texmade2 May. 12 at 3:03 PM

$CMPS WHAT A PAYDAY THIS JEWL IS GOING TO BE.

0 · Reply

Market Cap	1.24B
Revenue (ttm)	0.00
Net Income (ttm)	-287.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-0.60

Volume	1,805,500
Avg Vol	3,742,678
Day's Range	N/A - N/A
Shares Out	128.92M
Stochastic %K	66%
Beta	2.39
Analysts	Strong Sell
Price Target	$21.03